<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338426</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FAVC-CT-301</org_study_id>
    <nct_id>NCT03338426</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia</brief_title>
  <acronym>FIESTA</acronym>
  <official_title>A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the efficacy and safety by comparing the
      fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the
      placebo/atorvastatin treatment group respectively at Week 8 in patients with essential
      hypertension and dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SiSBP</measure>
    <time_frame>8weeks from Baseline Visit</time_frame>
    <description>The change in Sitting systolic blood pressure(SiSBP) from baseline in the test group(Fimasartan 120mg/Atorvastatin 40mg) at Week 8 compared to the Active Comparator group 2(Atorvastatin 40mg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>8weeks from Baseline Visit</time_frame>
    <description>The change in LDL-C from baseline in the test group at Week 8 compared to the active comparator group 1(fimasartan 120 mg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SiSBP</measure>
    <time_frame>8weeks from Baseline Visit</time_frame>
    <description>The change in Sitting systolic blood pressure(SiSBP) from baseline in the test group(Fimasartan 120mg/Atorvastatin 40mg) at Week 8 compared to the Active Comparator group 1(Fimasartan 120mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C</measure>
    <time_frame>8weeks from Baseline Visit</time_frame>
    <description>The change in LDL-C from baseline in the test group(Fimasartan 120mg/Atorvastatin 40mg) at Week 8 compared to the Active Comparator group 2(Atorvastatin 40mg)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Essential Hypertension, Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of a fixed dose combination of Fimasartan 120mg and Atorvastatin 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Co-administration of Fimasartan 120mg and Placebo for Atorvastatin 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Co-administration of Atorvastatin 40mg and Placebo for Fimasartan 120mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan 120mg</intervention_name>
    <description>Fimasartan 120mg will be administrated once daily for 8 weeks treatment period</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Active Comparator 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40mg</intervention_name>
    <description>Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Active Comparator 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Fimasartan 120mg</intervention_name>
    <description>Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period</description>
    <arm_group_label>Active Comparator 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Atorvastatin 40mg</intervention_name>
    <description>Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period</description>
    <arm_group_label>Active Comparator 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily provided a written consent to participate in this clinical study

          2. Male or female adults aged 19-70 years

          3. Patients must have been confirmed essential hypertension and dyslipidemia at Screening
             visit (V1)

          4. Uncontrolled blood pressure (140 mmHg ≤ mean SiSBP &lt; 180 mmHg) at the pre- baseline
             visit (V2) after wash-out period

          5. Able to understand this study, be cooperative in the execution of the study, and
             participate in the study until its completion

        Exclusion Criteria:

          1. Severe hypertension with mean Sitting systolic blood pressure(SiSBP)≥180 mmHg or
             Sitting diastolic blood pressure(SiDBP) ≥110 mmHg at the screening visit (V1) and the
             pre-baseline visit (V2), or orthostatic hypotension accompanied by symptoms

          2. Difference of mean Sitting systolic blood pressure(SiSBP) ≥ 20 mmHg and Sitting
             diastolic blood pressure(SiDBP) ≥ 10 mmHg between Lt and Rt arms at the screening
             visit (V1)

          3. Secondary hypertension patients: Secondary hypertension is not limited to the
             following diseases; (e.g., renovascular disease, adrenal medullary and cortical
             hyperfunctions, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral
             renal artery stenosis, Cushing's syndrome, pheochromocytoma, and polycystic kidney
             disease)

          4. Uncontrolled diabetes mellitus (currently on insulin, or HbA1c &gt;9% at the pre-baseline
             visit (V2)), or uncontrolled hypothyroidism (TSH ≥1.5 times the upper limit at the
             pre-baseline visit (V2))

          5. Heart disease (heart failure of New York Heart Association (NYHA) class 3 and 4), or
             ischemic heart disease (angina pectoris, myocardial infarction), peripheral vascular
             diseasenewly diagnosed within 6 months prior to the screening visit (V1), percutaneous
             transluminal coronary angioplasty, or coronary artery bypass graft, etc.

          6. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter;
             or other arrhythmia conditions that are determined to be clinically significant by the
             investigator

          7. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease,
             aortic stenosis, or hemodynamically significant aortic valve stenosis or mitral valve
             stenosis

          8. Cerebrovascular disorder (stroke, cerebral infarction, transient cerebral ischemic
             attack, cerebral hemorrhage, etc. within 6 months prior to the screening visit (V1)

          9. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae-Jin Nah</last_name>
    <phone>82-2-708-8000</phone>
    <email>jj.nah@boryung.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok-min Kang, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

